Twist Bioscience Corp TWST
Deals with insiders in the proxy filed Jan 6, 2026
Proxy, Item 404Deals between TWST and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Jan 6, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Jan 6, 2025.
Policies and Procedures for Related Party Transactions“On May 2, 2025, we executed a contribution agreement (the “Contribution Agreement”) with Atlas Data Storage, Inc. (“Atlas”), then a newly formed company, for the sale and transfer to Atlas of our DNA digital data storage assets, including the related intellectual property, equipment and contracts and the license of certain other intellectual property for a consideration of 73.0 million shares of Series Seed-1 Preferred Stock of Atlas, upfront cash consideration of $2.5 million, promissory notes of $2.0 million, contingent manufacturing and commercial milestone payments of up to $75.0 million, and royalty payments based on a percentage of Atlas sales of the DNA data storage products or services. Mr. Crandell, one of our directors, is a managing director of ARCH, which was one of the lead investors in the concurrent private placement of Atlas preferred stock. Upon the closing of the transaction, both Mr. Crandell and Dr. Leproust, our CEO and Board Chair, became members of the Atlas Board.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Party Transactions“We agreed to provide transitional support services to Atlas in the areas of accounting, payroll and IT in return for payment on a time and material basis pursuant to a transition services agreement with Atlas, which also provides for continued access to relevant systems and other relevant premises on a transitional basis and reimbursement of third-party vendor costs for procurement of goods and services on behalf of Atlas. As part of the Contribution Agreement, we also subleased specific office and lab space to Atlas in South San Francisco. We received a security deposit of $0.2 million for the sublease agreement and received approximately $1.1 million under the sublease agreement in fiscal year 2025.”
Read it in the proxyopen_in_new
New wording of the review policy 1 paragraph without an amount or a name
Policies and Procedures for Related Party Transactions“We are a party to a master supply agreement with, and are a supplier to, GeneDx Holding Corp.”
Read it in the proxyopen_in_new
The whole section
As filed
6 paragraphs quoted as filed
Policies and Procedures for Related Party Transactions“Our audit and risk committee charter states that our audit and risk committee is responsible for reviewing and approving in advance any related party transaction. Our Board adopted a written related person transaction policy setting forth the policies and procedures for the review and approval or ratification of related person transactions by the audit and risk committee. Pursuant to the policy, all of our directors, officers and employees are required to report to the audit and risk committee prior to entering into any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we are to be a participant, the amount involved exceeds $120,000 and a related person had or will have a direct or indirect material interest, including purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Party Transactions“We are a party to a master supply agreement with, and are a supplier to, GeneDx Holding Corp.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Party Transactions“(“GeneDx”), to provide them with reagents, equipment and other materials. Dr. Leproust, our CEO and Board Chair, is a member of the GeneDx Board and serves on its audit, compensation and nominating and corporate governance committees. In fiscal year 2025, Twist recognized $9.9 million in revenue from GeneDx. The terms for the master supply agreement and our commercial relationship with GeneDx reflect our standard commercial terms and are consistent with Twist’s customary commercial practices with its customers. Dr. Leproust was not involved in the negotiation of the master supply agreement and has no interest in transactions with GeneDx beyond her interest in any commercial transaction between the Company and its customer.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Party Transactions“We are a supplier to GRAIL. Mr. Ragusa, one of our directors and a member of our audit and risk and compensation committees is GRAIL’s CEO. In fiscal year 2025, Twist recognized $2.2 million in revenue from GRAIL. The terms for these sales and Twist’s commercial relationships with GRAIL reflect Twist’s standard commercial terms and are consistent with Twist’s customer commercial practices with its customers. Mr. Ragusa has no interest in GRAIL’s transactions with Twist beyond his interest in any commercial transaction between GRAIL and one of its suppliers.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Party Transactions“On May 2, 2025, we executed a contribution agreement (the “Contribution Agreement”) with Atlas Data Storage, Inc. (“Atlas”), then a newly formed company, for the sale and transfer to Atlas of our DNA digital data storage assets, including the related intellectual property, equipment and contracts and the license of certain other intellectual property for a consideration of 73.0 million shares of Series Seed-1 Preferred Stock of Atlas, upfront cash consideration of $2.5 million, promissory notes of $2.0 million, contingent manufacturing and commercial milestone payments of up to $75.0 million, and royalty payments based on a percentage of Atlas sales of the DNA data storage products or services. Mr. Crandell, one of our directors, is a managing director of ARCH, which was one of the lead investors in the concurrent private placement of Atlas preferred stock. Upon the closing of the transaction, both Mr. Crandell and Dr. Leproust, our CEO and Board Chair, became members of the Atlas Board.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Party Transactions“We agreed to provide transitional support services to Atlas in the areas of accounting, payroll and IT in return for payment on a time and material basis pursuant to a transition services agreement with Atlas, which also provides for continued access to relevant systems and other relevant premises on a transitional basis and reimbursement of third-party vendor costs for procurement of goods and services on behalf of Atlas. As part of the Contribution Agreement, we also subleased specific office and lab space to Atlas in South San Francisco. We received a security deposit of $0.2 million for the sublease agreement and received approximately $1.1 million under the sublease agreement in fiscal year 2025.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TWST/export.csv") into a cell.